Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management. (Q51169865)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2011

Language	Label	Description	Also known as
English	Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management.	scientific article published in October 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management. (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

Stephen M Ansell

1

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

publication date

1 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

86

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

10

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

851-858

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

The epidemiology of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Genetics of Hodgkin's and non-Hodgkin's lymphoma: a review

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Pseudoautosomal linkage of Hodgkin disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Vinorelbine: a new promising drug in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22105

21 January 2018

Identifiers

10.1002/AJH.22105

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

release_lz3n5ql23jgg5e3mtwyawdj5hi

1 reference

https://api.fatcat.wiki/v0/release/lz3n5ql23jgg5e3mtwyawdj5hi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 March 2018

http://europepmc.org/abstract/MED/21922525

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51169865&oldid=1844625095"